KaloBios Pharmaceuticals Inc’s ( KBIO ) share price has entered into oversold territory with an RSI value of 24.4. The Zacks Consensus Estimate for KaloBios for the full year period has improved 8 cents over the past two months to -$1.40 per share. Currently, KaloBios has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on ( KBIO ) after its recent drop.
KALOBIOS PHARMACEUTICALS INC (KBIO): Free Stock Analysis Report
Zacks Investment Research
- Personal Investing Ideas & Strategies
- Investment & Company Information